| Name | Company | P/L % | MPV |
|
|---|---|---|---|---|
| Lord Glendonbrook |
|
Stryker / NYQ:SYK | 408.46% | £355,919.05 |
| Lord Glendonbrook |
|
Abbott Laboratories / NYQ:ABT | 387.92% | £341,546.28 |
| Lord Sassoon |
|
Abbott Laboratories / NYQ:ABT | 274.71% | £262,297.85 |
| Lord Grabiner |
|
Boston Scientific / NYQ:BSX | 138.22% | £166,757.37** |
| Baroness Noakes |
|
Smith & Nephew / NYQ:SNN | 56.29% | £109,402.15 |
| Lord Glendonbrook |
|
Smith & Nephew / NYQ:SNN | 45.06% | £101,539.30 |
| Lord Mance |
|
Stryker / NYQ:SYK | 28.35% | £89,846.91 |
| Lord Londesborough |
|
Abbott Laboratories / NYQ:ABT | 13.29% | £79,301.60 |
| Lord Glendonbrook |
|
Medtronic / NYQ:MDT | 10.66% | £77,463.33** |
| Lord Sassoon |
|
Medtronic / NYQ:MDT | -1.01% | £69,291.46 |
| Lord Howard of Rising |
|
Ekf Diagnostics / LSE:EKF.L | -12.04% | £61,574.87 |
| Lord Glendonbrook |
|
Align Technology / NMS:ALGN | -40.14% | £41,902.83 |
| Lord Browne of Madingley | Allurion / NYQ:ALUR | -49.85% | £35,105.74 | |
| Lord Kakkar | Cyte / NMS:CTKB | -55.35% | £31,251.50** |